Free shipping on all orders over $ 500

BMN-673 8R,9S

Cat. No. M4854

All AbMole products are for research use only, cannot be used for human consumption.

BMN-673 8R,9S Structure
Synonym:

Talazoparib (8R,9S); (8R,9S)-LT-673

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 160 In stock
2mg USD 90 In stock
5mg USD 150 In stock
10mg USD 240 In stock
50mg USD 600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BMN673 is an orally bioavailable inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. BMN-673 has been proven to be highly active in mouse models of human cancer and also appears to be more selectively cytotoxic with a longer half-life and better bioavailability as compared to other compounds in development. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. Oral dosing of BMN 673 results in complete regression of the BRCA-deficient tumors in xenograft tumor model studies. In addition, we found that tumor cells with PTEN mutation are highly sensitive to BMN 673 treatment in vitro. Xenograft tumor models that harbor PTEN deficiency responded to oral BMN 673 treatment with significant tumor growth delay. Currently, BMN 673 is in phase 1 clinical trials with solid tumors or hematological malignancies.

Chemical Information
Molecular Weight 380.35
Formula C19H14F2N6O
CAS Number 1207456-00-5
Solubility (25°C) DMSO ≥ 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Yuqiao, et al. Mol Cancer Ther. Structure and preclinical characterization of BMN 673, a potent and orally active PARP inhibitor as an anticancer agent.

[2] Ying, et al. Mol Cancer Ther. Correlation of pharmacokinetics (PK), pharmacodynamics (PD) and in vivo antitumor activity of BMN 673 in preclinical models.

Related PARP Products
ABT-888

ABT-888 (Veliparib) is a potent inhibitor of PARP-1 and PARP-2 with Ki values of 5.2nM and 2.9nM respectively.

AG-014699 phosphate

AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM.

AG14361

AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM.

AZD2281 (Olaparib)

AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator.

Talazoparib

Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: BMN-673 8R,9S, Talazoparib (8R,9S); (8R,9S)-LT-673 supplier, PARP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.